Table 2.

Predictors of sustained virologic response among those treated with boceprevir- or telaprevir-based regimens

	Odds ratio univariable	95% CI	Odds ratio multivariable	95% CI
Age, for each 10 year increase	0.85	0.76, 0.95	0.94	0.83, 1.07
Sex, male vs female	1.04	0.7, 1.56	1.03	0.66, 1.61
Race/ethnicity
White	1
Black	0.67	0.56, 0.8	0.72	0.59, 0.87
Hispanic	1.24	0.78, 1.96	1.3	0.78, 2.15
Other	1.13	0.89, 1.43	1.19	0.92, 1.54
Body mass index, each one unit	0.99	0.97, 1.004	0.99	0.96, 1.01
increase in kg/m2
Body mass index
<30 vs ≥30 kg/m2	1.1	0.94, 1.29	1.05	0.79, 1.39
Cirrhosis	0.54	0.45, 0.65	0.42	0.34, 0.53
Treatment experienced Ms treatment	0.66	0.56, 0.78	0.76	0.63, 0.91
naive
Completed full course of treatment	2.63	2.24, 3.08	2.52	2.12, 3.00
HCV RNA, log IU/mL	0.91	0.88, 0.94	0.91	0.87, 0.94
Baseline alanine aminotransferase	1.002	1.001, 1.004	1.004	1.002, 1.01
level, U/L
Presence of diabetes	0.78	0.64, 0.95	0.89	0.72, 1.11
ESA use	0.93	0.78, 1.1	0.85	0.70, 1.03
Use of statins	1.18	0.92, 1.5	1.29	0.99, 1.70
Anaemia at baseline	0.56	0.41, 0.78	0.75	0.52, 1.07
Anaemia on treatment	2.04	1.49, 2.78	1.95	1.34, 2.83
Genotype (1a is the comparator group)
1b	1	0.81, 1.24	1.06	0.85, 1.33
Not specified	1.1	0.85, 1.41	1.14	0.87, 1.49
BOC vs TPV (TPV is the	1.04	0.84, 1.29	0.82	0.65, 1.05
comparator group)

BOC, boceprevir-containing regimen; TPV, telaprevir-containing regimen; ESA, erythropoiesis-stimulating agent.